Følg
Jakob B. Seidelin
Jakob B. Seidelin
Clinical scientist MD PhD DMSc, Rigshospitalet, University of Copenhagen
Verificeret mail på dadlnet.dk - Startside
Titel
Citeret af
Citeret af
År
Established and emerging biological activity markers of inflammatory bowel disease
OH Nielsen, B Vainer, SM Madsen, JB Seidelin, NHH Heegaard
The American Journal of Gastroenterology 95 (2), 359-367, 2000
299*2000
MAP kinases in inflammatory bowel disease
M Coskun, J Olsen, JB Seidelin, OH Nielsen
Clinica Chimica Acta 412 (7), 513-520, 2011
1842011
IL-33 is upregulated in colonocytes of ulcerative colitis
JB Seidelin, JT Bjerrum, M Coskun, B Widjaya, B Vainer, OH Nielsen
Immunology Letters 128 (1), 80-85, 2010
1802010
ATG16L1: A multifunctional susceptibility factor in Crohn disease
M Salem, M Ammitzboell, K Nys, JB Seidelin, OH Nielsen
Autophagy 11 (4), 585-594, 2015
1772015
Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome‐wide gene expression data
J Olsen, TA Gerds, JB Seidelin, C Csillag, JT Bjerrum, JT Troelsen, ...
Inflammatory Bowel Diseases 15 (7), 1032-1038, 2009
1282009
Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation
J Pedersen, EC LaCasse, JB Seidelin, M Coskun, OH Nielsen
Trends in Molecular Medicine 20 (11), 652-665, 2014
1192014
Micro-RNA profile in inflammatory bowel disease
M Coskun, JT Bjerrum, JB Seidelin, OH Nielsen
World J Gastroenterol 15 (45), 5751-5753, 2009
119*2009
miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis
M Coskun, JT Bjerrum, JB Seidelin, JT Troelsen, J Olsen, OH Nielsen
World journal of gastroenterology: WJG 19 (27), 4289, 2013
1182013
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
C Steenholdt, A Molazahi, MA Ainsworth, J Brynskov, OØ Thomsen, ...
Scandinavian Journal of Gastroenterology 47 (5), 518-527, 2012
1132012
Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients
T Blixt, KO Gradel, C Homann, JB Seidelin, K Schønning, A Lester, ...
Gastroenterology 152 (5), 1031-1041. e2, 2017
1052017
Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis
S Thorsteinsdottir, T Gudjonsson, OH Nielsen, B Vainer, JB Seidelin
Nature reviews Gastroenterology & hepatology 8 (7), 395-404, 2011
1042011
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised …
L Peyrin-Biroulet, A Hart, P Bossuyt, M Long, M Allez, P Juillerat, ...
The lancet Gastroenterology & hepatology 7 (2), 128-140, 2022
992022
Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies
M Boyd, M Thodberg, M Vitezic, J Bornholdt, K Vitting-Seerup, Y Chen, ...
Nature communications 9 (1), 1661, 2018
992018
Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease
FEO Holmberg, JB Seidelin, X Yin, BE Mead, Z Tong, Y Li, JM Karp, ...
EMBO molecular medicine 9 (5), 558-570, 2017
842017
Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement
JFKF Ilvemark, T Hansen, TM Goodsall, JB Seidelin, H Al-Farhan, ...
Journal of Crohn's and Colitis 16 (4), 554-580, 2022
832022
Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a Danish prospective population-based cohort study
M Attauabi, A Poulsen, K Theede, N Pedersen, L Larsen, T Jess, ...
Journal of Crohn's and Colitis 15 (4), 540-550, 2021
822021
COX-2–PGE2 signaling impairs intestinal epithelial regeneration and associates with TNF inhibitor responsiveness in ulcerative colitis
Y Li, C Soendergaard, FH Bergenheim, DM Aronoff, G Milne, LB Riis, ...
EBioMedicine 36, 497-507, 2018
792018
Soluble L-selectin levels predict survival in sepsis
JB Seidelin, OH Nielsen, J Strøm
Intensive Care Medicine 28 (11), 1613-1618, 2002
772002
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
S Vermeire, PL Lakatos, T Ritter, S Hanauer, B Bressler, R Khanna, ...
The Lancet Gastroenterology & Hepatology 7 (1), 28-37, 2022
682022
A role for interleukin-33 in TH2-polarized intestinal inflammation
JB Seidelin, G Rogler, OH Nielsen
Mucosal Immunology 4 (5), 496-502, 2011
622011
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20